share_log

Invivyd | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-GV 2019, L.P.(0.0%),GV 2019 GP, L.P.(0.0%), etc.

Invivyd | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-GV 2019, L.P.(0.0%),GV 2019 GP, L.P.(0.0%), etc.

Invivyd | SC 13G/A:超過5%持股股東披露文件(修正)-GV 2019, L.P.(0.0%),GV 2019 GP, L.P.(0.0%)等
美股SEC公告 ·  2024/11/09 08:25

牛牛AI助理已提取核心訊息

On September 30, 2024, a group of related entities including GV 2019, L.P., GV 2019 GP, L.P., GV 2019 GP, L.L.C., GV 2021, L.P., GV 2021 GP, L.P., GV 2021 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc., collectively known as the Reporting Persons, filed an amendment with the United States Securities and Exchange Commission to report that they have ceased to be beneficial owners of more than 5% of Invivyd, Inc.'s common stock. This amendment, identified as Schedule 13G/A, indicates that as of September 30, 2024, the Reporting Persons collectively own 0.0% of Invivyd's issued common stock, which is calculated based on 119,442,635 shares outstanding as of August 1, 2024. The initial statement was filed on February 14, 2022, and this recent amendment confirms the change in ownership status. Invivyd, Inc., formerly known as Adagio Therapeutics, Inc., is headquartered in Waltham, MA, and the Reporting Persons are associated with entities organized in Delaware, with a principal business office located at 1600 Amphitheatre Parkway, Mountain View, CA.
On September 30, 2024, a group of related entities including GV 2019, L.P., GV 2019 GP, L.P., GV 2019 GP, L.L.C., GV 2021, L.P., GV 2021 GP, L.P., GV 2021 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc., collectively known as the Reporting Persons, filed an amendment with the United States Securities and Exchange Commission to report that they have ceased to be beneficial owners of more than 5% of Invivyd, Inc.'s common stock. This amendment, identified as Schedule 13G/A, indicates that as of September 30, 2024, the Reporting Persons collectively own 0.0% of Invivyd's issued common stock, which is calculated based on 119,442,635 shares outstanding as of August 1, 2024. The initial statement was filed on February 14, 2022, and this recent amendment confirms the change in ownership status. Invivyd, Inc., formerly known as Adagio Therapeutics, Inc., is headquartered in Waltham, MA, and the Reporting Persons are associated with entities organized in Delaware, with a principal business office located at 1600 Amphitheatre Parkway, Mountain View, CA.
2024年9月30日,GV 2019,L.P.,GV 2019 GP,L.P.,GV 2019 GP,L.L.C.,GV 2021,L.P.,GV 2021 GP,L.P.,GV 2021 GP,L.L.C.,Alphabet Holdings LLC,XXVI Holdings Inc.和alphabet inc等相關實體集體稱爲報告人向美國證券交易委員會提交修正案,報告他們已停止是Invivyd, Inc.普通股的5%以上的受益所有者。這份修正案被標識爲13G/A表,顯示到2024年9月30日時,報告人共擁有Invivyd已發行普通股的0.0%,根據2024年8月1日的已發行股份爲11,9...展開全部
2024年9月30日,GV 2019,L.P.,GV 2019 GP,L.P.,GV 2019 GP,L.L.C.,GV 2021,L.P.,GV 2021 GP,L.P.,GV 2021 GP,L.L.C.,Alphabet Holdings LLC,XXVI Holdings Inc.和alphabet inc等相關實體集體稱爲報告人向美國證券交易委員會提交修正案,報告他們已停止是Invivyd, Inc.普通股的5%以上的受益所有者。這份修正案被標識爲13G/A表,顯示到2024年9月30日時,報告人共擁有Invivyd已發行普通股的0.0%,根據2024年8月1日的已發行股份爲11,944,263,500股計算。初始報告於2022年2月14日提交,最近的修正案證實了所有權狀況的變化。總部位於馬薩諸塞州沃爾瑟姆的Invivyd, Inc.,曾用名Adagio Therapeutics, Inc.,與總部位於加州山景城,以德拉華州組織的實體有關,主營業務地點位於1600 Amphitheatre Parkway。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。